The IMMU chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMU chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IMMU stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IMMU Detailed Price Forecast - CNN Money||View IMMU Detailed Summary - Google Finance|
|View IMMU Detailed Summary - Yahoo! Finance||View IMMU Stock Research & Analysis - Zacks.com|
|View IMMU Trends & Analysis - Trade-Ideas||View IMMU Major Holders - Barrons|
|View IMMU Call Transcripts - NASDAQ||View IMMU Breaking News & Analysis - Seeking Alpha|
|View IMMU Annual Report - CompanySpotlight.com||View IMMU OTC Short Report - OTCShortReport.com|
|View IMMU Fundamentals - TradeKing||View IMMU SEC Filings - Bar Chart|
|View Historical Prices for IMMU - The WSJ||View Performance/Total Return for IMMU - Morningstar|
|View the Analyst Estimates for IMMU - MarketWatch||View the Earnings History for IMMU - CNBC|
|View the IMMU Earnings - StockMarketWatch||View IMMU Buy or Sell Recommendations - MacroAxis|
|View the IMMU Bullish Patterns - American Bulls||View IMMU Short Pain Metrics - ShortPainBot.com|
|View IMMU Stock Mentions - StockTwits||View IMMU Stock Mentions - PennyStockTweets|
|View IMMU Stock Mentions - Twitter||View IMMU Investment Forum News - Investor Hub|
|View IMMU Stock Mentions - Yahoo! Message Board||View IMMU Stock Mentions - Seeking Alpha|
|View Insider Transactions for IMMU - SECform4.com||View Insider Transactions for IMMU - Insider Cow|
|View IMMU Major Holdings Summary - CNBC||View Insider Disclosure for IMMU - OTC Markets|
|View Insider Transactions for IMMU - Yahoo! Finance||View Institutional Holdings for IMMU - NASDAQ|
|View IMMU Stock Insight & Charts - FinViz.com||View IMMU Investment Charts - StockCharts.com|
|View IMMU Stock Overview & Charts - BarChart||View IMMU User Generated Charts - Trading View|
FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
Posted on Wednesday July 18, 2018
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease. The PDUFA target action date is January 18, 2019.
Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks
Posted on Wednesday July 11, 2018
WallStEquities.com observes the following stocks for today: Five Prime Therapeutics Inc. (NASDAQ: FPRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Immunomedics Inc. (NASDAQ: IMMU), and Incyte Corp. (NASDAQ: INCY). Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. rose 1.02%, ending Tuesday's trading session at $16.87.
How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)?
Posted on Wednesday June 27, 2018
Stocks with market capitalization between $2B and $10B, such as Immunomedics Inc (NASDAQ:IMMU) with a size of US$4.32b, do not attract as much attention from the investing community as doRead More...
[$$] Immunomedics Chairman Buys $19M More in Stock
Posted on Thursday June 21, 2018
Two weeks ago, B. Riley analyst Madhu Kumar gushed about Immunomedics, writing in a report that the biotech could have a “blockbuster cancer drug” in IMMU-132, an antibody-drug conjugate that had shown promise in disrupting “multiple solid cancers.” Kumar initiated coverage of the biotech on June 6 at Buy with a $53 price target. On Friday, Immunomedics (IMMU) Chairman Behzad Aghazadeh bought $18.5 million worth of the company’s stock through venBio Select Fund, a hedge fund where he serves as managing partner and portfolio manager. Aghazadeh bought 575,000 Immunomedics shares through the company’s public offering at $24 each, and went to the open market to buy another 200,000 shares for a better average per-share price of $23.39.